A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Latest Information Update: 13 Jan 2025
At a glance
- Drugs GNOS-PV01 (Primary) ; INO 9012 (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- 08 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 06 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 22 May 2023 Planned End Date changed from 13 Apr 2023 to 31 Dec 2023.